Indivior PLC (LON:INDV – Get Free Report) shares dropped 15.7% during trading on Thursday . The stock traded as low as GBX 548.71 ($6.93) and last traded at GBX 732 ($9.25). Approximately 1,888,371 shares traded hands during trading, an increase of 166% from the average daily volume of 709,477 shares. The stock had previously closed at GBX 868 ($10.97).
Wall Street Analysts Forecast Growth
Separately, Jefferies Financial Group restated a “buy” rating and set a GBX 1,800 ($22.74) price target on shares of Indivior in a research report on Tuesday, December 17th.
Read Our Latest Stock Analysis on INDV
Indivior Stock Performance
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Further Reading
- Five stocks we like better than Indivior
- What is the Nasdaq? Complete Overview with History
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- What is the NASDAQ Stock Exchange?
- DuPont’s Electronics Spinoff: The Start of Something Big
- With Risk Tolerance, One Size Does Not Fit All
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.